These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Emerging strategies for the treatment of Meibomian gland dysfunction].
    Author: Ruan F, Jie Y.
    Journal: Zhonghua Yan Ke Za Zhi; 2019 Jun 11; 55(6):465-468. PubMed ID: 31189276.
    Abstract:
    Meibomian gland dysfunction (MGD), as a chronic,diffuse Meibomian gland disease,is one of the most common ophthalmological clinical diseases. Symptoms can be mild,such as ocular discomfort, but severe cases resulting in ocular surface damage could affect patients' visual function. Moreover,with the absence of a thorough examination of eyelid status and Meibomian gland prior to ocular surface surgery, it could cause severe postoperative complications. As a usual but easily overlooked disease, MGD and its associated ocular surface diseases have drawn greater attention,on the other hand,some emerging therapies,in addition to the clinically recognized treatments, provided doctors with more effective treatments at their disposal,and plenty of research achievements have been published. This article emphasizes on new physical approaches in the treatments of MGD and its associated ocular surface diseases. (Chin J Ophthalmol, 2019,55:465-468). 睑板腺功能障碍（MGD）是一种临床常见的慢性、弥漫性睑板腺病变。轻者引起眼部不适症状，重者可导致眼表组织损伤，影响患者视功能，且可使眼表手术出现严重术后并发症。物理治疗是MGD最主要的临床治疗方法，近年不断出现的新方法也取得了良好的治疗效果。本文就MGD及其相关眼表损伤的物理治疗，对最新研究进展进行综述，以期为临床工作提供参考。（中华眼科杂志，2019，55：465-468）.
    [Abstract] [Full Text] [Related] [New Search]